Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:GALT NASDAQ:LYEL NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.59-3.4%$1.35$0.40▼$2.27$84.61M1.21822,139 shs58,779 shsGALTGalectin Therapeutics$5.01-5.5%$4.53$0.73▼$6.55$321.97M0.85385,595 shs48,569 shsLYELLyell Immunopharma$16.11-7.0%$13.69$7.65▼$30.00$309.38M-0.0775,352 shs2,450 shsUPXIUpexi$4.86-4.6%$6.58$1.90▼$22.57$286.56M-0.534.07 million shs1.06 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-0.61%-3.53%+35.54%+223.98%+9.33%GALTGalectin Therapeutics+4.13%+6.85%+10.42%+87.94%+101.52%LYELLyell Immunopharma-3.99%+2.73%+32.31%+57.60%-22.68%UPXIUpexi-11.01%-18.56%-22.64%-24.03%+30.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.59-3.4%$1.35$0.40▼$2.27$84.61M1.21822,139 shs58,779 shsGALTGalectin Therapeutics$5.01-5.5%$4.53$0.73▼$6.55$321.97M0.85385,595 shs48,569 shsLYELLyell Immunopharma$16.11-7.0%$13.69$7.65▼$30.00$309.38M-0.0775,352 shs2,450 shsUPXIUpexi$4.86-4.6%$6.58$1.90▼$22.57$286.56M-0.534.07 million shs1.06 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-0.61%-3.53%+35.54%+223.98%+9.33%GALTGalectin Therapeutics+4.13%+6.85%+10.42%+87.94%+101.52%LYELLyell Immunopharma-3.99%+2.73%+32.31%+57.60%-22.68%UPXIUpexi-11.01%-18.56%-22.64%-24.03%+30.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.57Moderate Buy$3.30108.20% UpsideGALTGalectin Therapeutics 2.00Hold$6.0019.74% UpsideLYELLyell Immunopharma 1.33Sell$15.00-6.86% DownsideUPXIUpexi 2.67Moderate Buy$15.50219.26% UpsideCurrent Analyst Ratings BreakdownLatest ALXO, GALT, UPXI, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ALXOALX OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LYELLyell ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALXOALX OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GALTGalectin TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LYELLyell ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025UPXIUpexiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ALYELLyell Immunopharma$60K5,156.28N/AN/A$26.21 per share0.61UPXIUpexi$15.81M18.08N/AN/A$1.01 per share4.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$24.29N/AN/AN/A-552,328.31%-85.58%-68.85%11/6/2025 (Estimated)UPXIUpexi-$13.68MN/A0.00∞N/A-86.54%-54.33%-31.28%N/ALatest ALXO, GALT, UPXI, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GALTGalectin Therapeutics-$0.11N/AN/AN/AN/AN/A11/6/2025Q3 2025ALXOALX Oncology-$0.37N/AN/AN/AN/AN/A11/6/2025Q3 2025LYELLyell Immunopharma-$2.81N/AN/AN/AN/AN/A8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/12/2025Q2 2025LYELLyell Immunopharma-$3.80-$2.89+$0.91-$2.89$0.00 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.114.524.52GALTGalectin TherapeuticsN/A1.431.43LYELLyell ImmunopharmaN/A7.657.65UPXIUpexiN/A1.741.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%GALTGalectin Therapeutics11.68%LYELLyell Immunopharma66.05%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%GALTGalectin Therapeutics50.10%LYELLyell Immunopharma22.30%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.55 million42.31 millionOptionableGALTGalectin Therapeutics964.06 million31.97 millionOptionableLYELLyell Immunopharma27019.21 million14.93 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableALXO, GALT, UPXI, and LYEL HeadlinesRecent News About These CompaniesUpexi (NASDAQ:UPXI) Shares Up 5.9% - Should You Buy?October 21 at 3:20 AM | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Upexi (NASDAQ:UPXI)October 16, 2025 | americanbankingnews.comUpexi (NASDAQ:UPXI) Given Sell (D-) Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comUpexi (UPXI) Valuation in Focus After Digital Asset Strategy Unveiled at Treasury ShowcaseOctober 13, 2025 | finance.yahoo.comCould Upexi's (UPXI) Digital Asset Treasury Push Reveal a New Core Strategy?October 11, 2025 | uk.finance.yahoo.comUpexi to Participate in Upcoming October Investor ConferencesOctober 6, 2025 | markets.businessinsider.comUpexi, Inc. to Participate in Multiple Investor Conferences in October 2025October 6, 2025 | quiverquant.comQUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestOctober 4, 2025 | marketbeat.comUpexi adds SOL Big Brain to advisory committeeSeptember 30, 2025 | msn.comUpexi Welcomes SOL Big Brain to the Upexi Advisory CommitteeSeptember 30, 2025 | markets.businessinsider.comKathmere Capital Management LLC Makes New Investment in Upexi, Inc. $UPXISeptember 27, 2025 | marketbeat.comUpexi (UPXI) Expected to Announce Earnings on MondaySeptember 25, 2025 | marketbeat.comUpexi Inc: Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 25, 2025 | finanznachrichten.deUpexi, Inc. Reports Financial Results for Fiscal Year 2025 and Provides Update on Solana Treasury PerformanceSeptember 24, 2025 | quiverquant.comQUpexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025September 24, 2025 | globenewswire.comUpexi Stock Pops Pre-Market, Retail Chatter Surges On Growing Solana Treasury HoldingsSeptember 12, 2025 | msn.comUpexi's Stellar Gains: Solana Treasury Strategy Drives 129% Growth in SOL ValueSeptember 12, 2025 | econotimes.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)September 11, 2025 | prnewswire.comUpexi Adjusted SOL per Share Increases 129% Since Treasury LaunchSeptember 11, 2025 | globenewswire.comSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8, 2025 | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALXO, GALT, UPXI, and LYEL Company DescriptionsALX Oncology NASDAQ:ALXO$1.58 -0.06 (-3.35%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Galectin Therapeutics NASDAQ:GALT$5.01 -0.29 (-5.45%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Lyell Immunopharma NASDAQ:LYEL$16.10 -1.22 (-7.02%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Upexi NASDAQ:UPXI$4.86 -0.24 (-4.62%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
